UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): July 2, 2007
INVERNESS MEDICAL INNOVATIONS, INC.
(Exact name of registrant as specified in its charter)
| |
|
|
|
|
| Delaware
|
|
1-16789
|
|
04-3565120 |
|
|
|
|
|
|
| (State or other jurisdiction of
|
|
(Commission File Number)
|
|
(IRS Employer |
| incorporation)
|
|
|
|
Identification No.) |
51 Sawyer Road, Suite 200
Waltham, Massachusetts 02453
(Address of principal executive offices, including zip code)
(781) 647-3900
(Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the
filing obligation of the registrant under any of the following provisions (see General Instruction
A.2. below):
þ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR 240.13e-4(c))
TABLE OF CONTENTS
Item 8.01 Other Events.
On July 2 & 3, 2007, the presentation attached hereto as Exhibit 99.1, and incorporated herein
by reference, was made to employees at Cholestech Corporation.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
| |
|
|
| Exhibit No. |
|
Description |
99.1
|
|
Company Overview presentation. |
Additional Information and Where To Find It
Inverness plans to file with the SEC a Registration Statement on Form S-4 in connection with
its proposed acquisition of Cholestech Corporation, and Cholestech plans to file with the SEC and
mail to its shareholders a Proxy Statement/Prospectus in connection with the transaction. The
Registration Statement and the Proxy Statement/Prospectus will contain important information about
Inverness, Cholestech, the transaction and related matters. Investors and security holders are
urged to read the Registration Statement and the Proxy Statement/Prospectus carefully when they are
available. Investors and security holders will be able to obtain free copies of the Registration
Statement and the Proxy Statement/Prospectus and other documents filed with the SEC by Inverness
and Cholestech through the web site maintained by the SEC at www.sec.gov. In addition, investors
and security holders will be able to obtain free copies of the Registration Statement and the Proxy
Statement/Prospectus from Inverness by contacting Shareholder Relations at (781) 647-3900 or
jon.russell@invmed.com or from Cholestech by contacting Jack Glenn at (510) 781-5065 or
jglenn@cholestech.com.
Inverness and its directors and executive officers may be deemed to be participants in the
solicitation of proxies from the shareholders of Cholestech in connection with the transaction
described herein. Information regarding the special interests of these directors and executive
officers in the transaction described herein will be included in the Proxy Statement/Prospectus
described above. Additional information regarding these directors and executive officers is also
included in Inverness’s proxy statement for its 2007 Annual Meeting of Stockholders, which was
filed with the SEC on or about April 9, 2007. This document is available free of charge at the
SEC’s web site at www.sec.gov and from Inverness by contacting Inverness at Shareholder Relations
at (781) 647-3900 or jon.russell@invmed.com.
Cholestech and its directors and executive officers also may be deemed to be participants in
the solicitation of proxies from the shareholders of Cholestech in connection with the transaction
described herein. Information regarding the special interests of these directors and executive
officers in the transaction described herein will be included in the Proxy Statement/Prospectus
described above. Additional information regarding these directors and executive officers is also
included in Cholestech’s proxy statement for its 2006 Annual Meeting of Shareholders, which was
filed with the SEC on or about July 17, 2006. This document is available free of charge at the
SEC’s web site at www.sec.gov and from Cholestech by contacting Jack Glenn at (510) 781-5065 or
jglenn@cholestech.com.